Drugmaker soars nearly 300% on successful trial
Intercept Pharmaceuticals' stock price rockets to $285 after a test of its liver treatment was stopped early.
By Christopher Freeburn
Intercept Pharmaceuticals said the trial of obeticholic acid (OCA) was stopped after an analysis indicated that it had demonstrated its efficacy. Intercept CEO Mark Pruzanski hailed the news, saying "the unexpected early stopping of (the trial) due to OCA meeting the primary endpoint with such high significance is a major milestone."
The ICPT drug is meant to treat nonalcoholic steatohepatitis (NASH), a chronic condition affecting the liver. According to the National Digestive Diseases Information Clearinghouse, NASH "resembles alcoholic liver disease, but occurs in people who drink little or no alcohol" and can lead to cirrhosis.
The trial, which monitored patients receiving a daily 25 mg oral dose of OCA over a 72-week treatment period, showed a "highly statistically significant improvement" in patients receiving the ICPT treatment.
Based on the results, the Data Safety Monitoring Board recommended that the trial be halted.
ICPT went public in October 2012 at $15 per share. At mid-Thursday's price around $280, Intercept has returned more than 1,700% since going public.
More From InvestorPlace
A fairly quick google resulted in finding:
The drug is known as obeticholic acid and it's so old no one has a patent on it. One brokerage says the company may crack "2% of the market" for treating livers with it.
Apparently the only other treatment is to remove a small part of the liver. It's estimated that 2% to 5% of Americans between the ages of 40 and 50 have it and that few have it outside that age group.
No thanks! If the drug truly becomes a blockbuster the big kids on the block like Abbvie, Merck, Johnson & Johnson, Pfizer, etc. will eat this tiny company for lunch.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Serious issues like drought and the deterioration of the developed world spell opportunity for this industry leader.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.